• bitcoinBitcoin(BTC)$79,660.001.49%
  • ethereumEthereum(ETH)$2,518.111.54%
  • tetherTether(USDT)$1.000.00%
  • binancecoinBNB(BNB)$755.31-0.27%
  • rippleXRP(XRP)$1.443.38%
  • usd-coinUSDC(USDC)$1.000.01%
  • solanaSolana(SOL)$104.801.69%
  • tronTRON(TRX)$0.3394060.41%
  • Figure HelocFigure Heloc(FIGR_HELOC)$1.040.00%
  • zcashZcash(ZEC)$1,242.719.86%
  • HyperliquidHyperliquid(HYPE)$86.442.56%
  • dogecoinDogecoin(DOGE)$0.0911991.90%
  • RainRain(RAIN)$0.016111-4.29%
  • USDSUSDS(USDS)$1.000.01%
  • whitebitWhiteBIT Coin(WBT)$82.434.98%
  • moneroMonero(XMR)$502.59-4.22%
  • chainlinkChainlink(LINK)$12.49-1.51%
  • leo-tokenLEO Token(LEO)$9.18-0.29%
  • cardanoCardano(ADA)$0.2218431.81%
  • stellarStellar(XLM)$0.1903060.04%
  • bitcoin-cashBitcoin Cash(BCH)$260.051.33%
  • daiDai(DAI)$1.00-0.02%
  • Ethena USDeEthena USDe(USDE)$1.000.01%
  • USD1USD1(USD1)$1.000.00%
  • CantonCanton(CC)$0.1080303.33%
  • uniswapUniswap(UNI)$6.83-3.03%
  • litecoinLitecoin(LTC)$54.55-1.69%
  • the-open-networkGram (prev. Toncoin)(GRAM)$1.411.24%
  • hedera-hashgraphHedera(HBAR)$0.079900-0.29%
  • avalanche-2Avalanche(AVAX)$8.03-0.38%
  • suiSui(SUI)$0.820.61%
  • Global DollarGlobal Dollar(USDG)$1.00-0.02%
  • shiba-inuShiba Inu(SHIB)$0.0000050.90%
  • nearNEAR Protocol(NEAR)$2.455.70%
  • crypto-com-chainCronos(CRO)$0.0605504.94%
  • paypal-usdPayPal USD(PYUSD)$1.000.02%
  • BlackRock USD Institutional Digital Liquidity FundBlackRock USD Institutional Digital Liquidity Fund(BUIDL)$1.000.00%
  • MemeCoreMemeCore(M)$1.202.44%
  • tether-goldTether Gold(XAUT)$4,398.540.22%
  • Circle USYCCircle USYC(USYC)$1.140.01%
  • BittensorBittensor(TAO)$262.153.52%
  • Ripple USDRipple USD(RLUSD)$1.000.01%
  • okbOKB(OKB)$114.98-0.53%
  • Ondo US Dollar YieldOndo US Dollar Yield(USDY)$1.150.14%
  • mantleMantle(MNT)$0.654.85%
  • AsterAster(ASTER)$0.76-0.81%
  • aaveAave(AAVE)$130.78-0.06%
  • polkadotPolkadot(DOT)$1.1810.24%
  • pax-goldPAX Gold(PAXG)$4,402.710.23%
  • Pump.funPump.fun(PUMP)$0.0045165.87%
TradePoint.io
  • Main
  • AI & Technology
  • Stock Charts
  • Market & News
  • Business
  • Finance Tips
  • Trade Tube
  • Blog
  • Shop
No Result
View All Result
TradePoint.io
No Result
View All Result

Researchers developed a gene-editing technology that reduces 'bad' cholesterol

November 16, 2023
in AI & Technology
Reading Time: 2 mins read
A A
Researchers developed a gene-editing technology that reduces 'bad' cholesterol
ShareShareShareShareShare

In a trial run by , a Cambridge–based biotech company, researchers discovered that a single infusion of a gene-editing treatment called VERVE-101 was able to reduce cholesterol levels in patients. This treatment was tested in individuals with hereditary conditions that made them susceptible to developing clogged arteries and heart attacks. Scientists were able to use techniques to tweak liver gene cells. The researchers a cholesterol-raising gene called PCSK9, which is found in the liver, in order to lower — sometimes called “bad” cholesterol — which causes plaque to build up in arteries in the first place.

PCSK9 was lowered by as much as 84 percent in the cohorts that received higher infusion rates of the treatment. At those higher treatment doses, Verve scientists said that the reduction of those LDL-C-related proteins lasted in previous studies on primates.

YOU MAY ALSO LIKE

Meta Introduces Muse, a Personal AI Agent That Runs on Its Own Dedicated Secure Cloud Computer

OpenAI Says Internal AI System Resolved the Navier–Stokes Problem – Unite.AI

Verve Therapeutics

From a clinical standpoint, this gene editing therapy has the potential to disrupt the current standard treatment for high cholesterol. The current go-to’s include prescription statins and PCSK9 inhibitors, but they require strict adherence and can have

CRISPR, while seemingly miraculous, is a long way from replacing daily medications though. According to , two of the 10 participants in the study suffered from a “cardiovascular event” that coincided with the infusion. Verve says one was not related to the treatment at all and the second was “potentially related to treatment due to proximity to dosing.” The use of a gene-editing technology will always carry some risk because the edits .

Before a single infusion therapy for high cholesterol can reach consumers, the that the treatment will need to be studied for up to 15 years. Verve recently received FDA clearance for an for VERVE-101, meaning that the company can begin to conduct trials in the US. The current trials in New Zealand and the United Kingdom will look for willing clinical trial participants to expand the study.

This article originally appeared on Engadget at https://www.engadget.com/researchers-developed-a-gene-editing-technology-that-reduces-bad-cholesterol-170040293.html?src=rss
Credit: Source link

ShareTweetSendSharePin

Related Posts

Meta Introduces Muse, a Personal AI Agent That Runs on Its Own Dedicated Secure Cloud Computer
AI & Technology

Meta Introduces Muse, a Personal AI Agent That Runs on Its Own Dedicated Secure Cloud Computer

September 9, 2026
OpenAI Says Internal AI System Resolved the Navier–Stokes Problem – Unite.AI
AI & Technology

OpenAI Says Internal AI System Resolved the Navier–Stokes Problem – Unite.AI

September 9, 2026
How To Watch Apple Unveil The New iPhones On September 9
AI & Technology

How To Watch Apple Unveil The New iPhones On September 9

September 9, 2026
NSA, CISA, FBI Warn China-Based AI Firms Distill US Frontier Models – Unite.AI
AI & Technology

NSA, CISA, FBI Warn China-Based AI Firms Distill US Frontier Models – Unite.AI

September 9, 2026
Next Post
UCLA Researchers Introduce ‘Rephrase and Respond’ (RaR): A New Artificial Intelligence Method that Enhances LLMs’ Understanding of Human Questions

UCLA Researchers Introduce 'Rephrase and Respond' (RaR): A New Artificial Intelligence Method that Enhances LLMs’ Understanding of Human Questions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Search

No Result
View All Result
Two Battlegrounds, One Sprint: Dems in Michigan and Maine Focus on Decisive Senate Seats | Jul 27

Two Battlegrounds, One Sprint: Dems in Michigan and Maine Focus on Decisive Senate Seats | Jul 27

September 4, 2026
NBC Nightly News with Tom Llamas Full Episode – July 28

NBC Nightly News with Tom Llamas Full Episode – July 28

September 3, 2026
Lindsay Clancy trial latest: Judge declares a mistrial – follow live – BBC

Lindsay Clancy trial latest: Judge declares a mistrial – follow live – BBC

September 4, 2026

About

Learn more

Our Services

Legal

Privacy Policy

Terms of Use

Bloggers

Learn more

Article Links

Contact

Advertise

Ask us anything

©2020- TradePoint.io - All rights reserved!

Tradepoint.io, being just a publishing and technology platform, is not a registered broker-dealer or investment adviser. So we do not provide investment advice. Rather, brokerage services are provided to clients of Tradepoint.io by independent SEC-registered broker-dealers and members of FINRA/SIPC. Every form of investing carries some risk and past performance is not a guarantee of future results. “Tradepoint.io“, “Instant Investing” and “My Trading Tools” are registered trademarks of Apperbuild, LLC.

This website is operated by Apperbuild, LLC. We have no link to any brokerage firm and we do not provide investment advice. Every information and resource we provide is solely for the education of our readers. © 2020 Apperbuild, LLC. All rights reserved.

No Result
View All Result
  • Main
  • AI & Technology
  • Stock Charts
  • Market & News
  • Business
  • Finance Tips
  • Trade Tube
  • Blog
  • Shop

© 2023 - TradePoint.io - All Rights Reserved!